Physician profile
Timothy E Quan
NPI 1649227208
$32,736.28
in general payments reported to CMS, 2019-2025
45 companies · $4,620 in 2025
The $4,620 reported for 2025 was more than what 85% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,339 · 2020: $4,292 · 2021: $4,890 · 2022: $4,593 · 2023: $5,199 · 2024: $4,803 · 2025: $4,620.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $14K · Education: $529.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $14,093.28 |
| Education | $528.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $5,411.53 | 2019-2025 | |
| Amgen INC. | $4,408.75 | 2019-2025 | Enbrel, Otezla, Krystexxa |
| Janssen Biotech, INC. | $3,376.80 | 2019-2025 | Tremfya, Simponi Aria, Stelara |
| Ucb, INC. | $2,917.39 | 2019-2025 | Bimzelx, Cimzia |
| Pfizer INC. | $1,787.53 | 2019-2023 | |
| Mallinckrodt Hospital Products INC. | $1,714.52 | 2020-2025 | Acthar |
| Astrazeneca Pharmaceuticals Lp | $1,691.75 | 2021-2025 | Saphnelo |
| Horizon Therapeutics Plc | $1,277.65 | 2019-2023 | Krystexxa |
| Genentech USA, INC. | $1,134.57 | 2019-2025 | Actemra, Rituxan, Gazyva |
| Lilly USA, LLC | $1,039.89 | 2019-2025 | Taltz, Zepbound |
| E.R. Squibb & Sons, L.L.C. | $1,038.86 | 2019-2025 | Orencia, Sotyktu |
| Glaxosmithkline, LLC. | $1,019.12 | 2019-2025 | Benlysta |
| Novartis Pharmaceuticals Corporation | $998.95 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $676.78 | 2019-2025 | Ofev, Cyltezo, Jascayd |
| Alexion Pharmaceuticals, INC. | $456.65 | 2019-2025 | Strensiq, Ultomiris |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Quan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.